"Advancements in TB Vaccine Trials: Progress in India and South Africa"

Bharat Biotech has initiated clinical trials of MTBVAC, a potentially more effective TB vaccine derived from a human source, in India. The vaccine, developed in collaboration with Spanish biopharma player Biofabri, aims to provide better protection against tuberculosis for newborns, adolescents, and adults. MTBVAC is designed to be more effective and longer-lasting than the existing BCG vaccine, particularly in preventing pulmonary TB. The clinical trials in India mark a significant step in the global effort to develop improved TB vaccines, with the potential to address the high burden of TB cases in the country.